Universe Pharmaceuticals (Universe Pharmaceuticals) COGS-to-Revenue : 0.70 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Universe Pharmaceuticals COGS-to-Revenue?

Universe Pharmaceuticals's Cost of Goods Sold for the six months ended in Sep. 2023 was $9.66 Mil. Its Revenue for the six months ended in Sep. 2023 was $13.84 Mil.

Universe Pharmaceuticals's COGS to Revenue for the six months ended in Sep. 2023 was 0.70.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Universe Pharmaceuticals's Gross Margin % for the six months ended in Sep. 2023 was 30.25%.

Universe Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Universe Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universe Pharmaceuticals COGS-to-Revenue Chart

Universe Pharmaceuticals Annual Data

Trend

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

COGS-to-Revenue

Get a 7-Day Free Trial

0.60

0.54

0.47

0.45

0.68

Universe Pharmaceuticals Semi-Annual Data
	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
COGS-to-Revenue	Get a 7-Day Free Trial						0.44	0.43	0.49	0.67	0.70

Universe Pharmaceuticals COGS-to-Revenue Calculation

Universe Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Sep. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	21.994	/	32.309
	=	0.68

Universe Pharmaceuticals's COGS to Revenue for the quarter that ended in Sep. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	9.655	/	13.842
	=	0.70

Universe Pharmaceuticals (NAS:UPC) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Universe Pharmaceuticals's Gross Margin % for the six months ended in Sep. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	9.655 / 13.842
	=	30.25 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Universe Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Universe Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Universe Pharmaceuticals (Universe Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Universe Pharmaceuticals Inc (NAS:UPC) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

265 Jingjiu Avenue, Economic & Technological Development Zone, Jinggangshan, Jiangxi, Ji’an, CHN

Website

http://www.universe-pharmacy.com

Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.